Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

5.58
-0.3800-6.38%
Post-market: 5.580.00000.00%19:18 EDT
Volume:1.90M
Turnover:10.63M
Market Cap:765.26M
PE:-1.46
High:5.85
Open:5.81
Low:5.49
Close:5.96
Loading ...

Pharma Stocks Survive Market Rout on Tariff Exemption, but Uncertainty Continues

Reuters
·
03 Apr

Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution

Simply Wall St.
·
31 Mar

Pharma Stocks Sink After Ouster of Top FDA Vaccine Regulator

Reuters
·
31 Mar

BRIEF-Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection

Reuters
·
13 Mar

Vir Biotechnology Enrolls First Patient in Phase 3 Chronic Hepatitis Delta Trial

MT Newswires Live
·
13 Mar

Vir Biotechnology Enrolls First Patient in Phase 3 Eclipse Registrational Program for Chronic Hepatitis Delta

THOMSON REUTERS
·
13 Mar

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Business Wire
·
13 Mar

CrowdStrike Fuels Partner Growth and Profitability with Expanded Accelerate Partner Program

Business Wire
·
11 Mar

Vir Biotechnology Is Maintained at Overweight by Barclays

Dow Jones
·
01 Mar

Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

Barclays Remains a Buy on Vir Biotechnology (VIR)

TIPRANKS
·
28 Feb

Stock Track | Vir Biotechnology Plummets 9.46% as Key Pipeline Programs Remain Early-Stage

Stock Track
·
28 Feb

Q4 2024 Vir Biotechnology Inc Earnings Call

Thomson Reuters StreetEvents
·
28 Feb

Stock Track | Vir Biotechnology Soars 5.98% on Strong Q4 Results and Promising Outlook

Stock Track
·
27 Feb

Vir Biotechnology Price Target Maintained With a $19.00/Share by Needham

Dow Jones
·
27 Feb

Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

GuruFocus.com
·
27 Feb

Vir Biotechnology Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
27 Feb

Vir Biotechnology reports Q4 EPS (76c), consensus (87c)

TIPRANKS
·
27 Feb

Vir Biotechnology Q4 GAAP EPS $(0.76) Beats $(0.87) Estimate, Sales $12.37M Beat $8.14M Estimate

Benzinga
·
27 Feb